Castle Biosciences, Inc. (CSTL) Earnings Call Analysis

NASDAQ · Healthcare · Diagnostics & Research

17/25

Growth 4 Margin 4 Expansion 5 Platform 0 Financial 4

latest quarter score

Earnings Reports

17
Castle Biosciences (CSTL) Q2 2026: TissueCypher Volumes Surge 63% as Pipeline Expansion Accelerates
July 31, 2026
14
Castle Biosciences (CSTL) Q1 2026: Tissue Cipher Volume Up 58%, Propelling Guidance Hike
May 07, 2026
17
Castle Biosciences (CSTL) Q4 2025: TissueCypher Volume Soars 86%, Reinforcing GI Franchise Trajectory
February 27, 2026
14
Castle Biosciences (CSTL) Q3 2025: DecisionDx Melanoma Surpasses 10,000 Quarterly Reports, Fueling Guidance Raise
November 04, 2025
14
Castle Biosciences (CSTL) Q2 2025: TissueCypher Volume Up 92%, Offsetting SCC Policy Drag
August 04, 2025
20
Castle Biosciences (CSTL) Q1 2025: TissueCypher Delivers 117% Growth, GI Expansion Accelerates
July 06, 2025
Castle Biosciences (CSTL) Q4 2024: 51% Revenue Growth Amid Medicare Coverage Headwinds on Key Test
February 27, 2025

Browse all companies